Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level
- PMID: 18314540
- DOI: 10.1165/rcmb.2007-0217OC
Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level
Abstract
Amiodarone interferes with the endocytic pathway, inhibits proteolysis, and causes the formation of vacuoles, but uptake and intracellular distribution of the drug, origin of vacuoles, and functional consequences of amiodarone accumulation remain unclear. Our objective was to study amiodarone uptake, clarify the origin of vacuoles, and investigate the effect of amiodarone on the life cycle of the coronavirus responsible for the Severe Acute Respiratory Syndrome (SARS), which, to enter cells, relies on the proteolytic cleavage of a viral spike protein by the endosomal proteinase cathepsin L. Using alveolar macrophages, we studied uptake of (125)I-amiodarone and (125)I-B2, an analog lacking the lateral group diethylamino-beta-ethoxy, and analyzed the effects of amiodarone on the distribution of endosomal markers and on the uptake of an acidotropic dye. Furthermore, using Vero cells, we tested the impact of amiodarone on the in vitro spreading of the SARS coronavirus. We found that (1) amiodarone associates with different cell membranes and accumulates in acidic organelles; (2) the diethylamino-beta-ethoxy group is an important determinant of uptake; (3) vacuoles forming upon exposure to amiodarone are enlarged late endosomes; (4) amiodarone inhibits the spreading in vitro of SARS coronavirus; and (5) trypsin cleavage of the viral spike protein before infection, which permits virus entry through the plasma membrane, does not impair amiodarone antiviral activity. We conclude that amiodarone alters late compartments of the endocytic pathway and inhibits SARS coronavirus infection by acting after the transit of the virus through endosomes.
Similar articles
-
SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells.J Biol Chem. 2006 Feb 10;281(6):3198-203. doi: 10.1074/jbc.M508381200. Epub 2005 Dec 8. J Biol Chem. 2006. PMID: 16339146 Free PMC article.
-
Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry.Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81. doi: 10.1073/pnas.0505577102. Epub 2005 Aug 4. Proc Natl Acad Sci U S A. 2005. PMID: 16081529 Free PMC article.
-
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.Virol J. 2005 Aug 22;2:69. doi: 10.1186/1743-422X-2-69. Virol J. 2005. PMID: 16115318 Free PMC article.
-
Recent developments in the virology and antiviral research of severe acute respiratory syndrome coronavirus.Infect Disord Drug Targets. 2007 Mar;7(1):29-41. doi: 10.2174/187152607780090739. Infect Disord Drug Targets. 2007. PMID: 17346209 Review.
-
Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research.Antiviral Res. 2013 Dec;100(3):605-14. doi: 10.1016/j.antiviral.2013.09.028. Epub 2013 Oct 8. Antiviral Res. 2013. PMID: 24121034 Free PMC article. Review.
Cited by
-
Targeting SARS-CoV-2 and host cell receptor interactions.Antiviral Res. 2023 Feb;210:105514. doi: 10.1016/j.antiviral.2022.105514. Epub 2022 Dec 26. Antiviral Res. 2023. PMID: 36581047 Free PMC article. Review.
-
Antiviral activity of amiodarone in SARS-CoV-2 disease.Physiol Res. 2022 Dec 16;71(6):869-875. doi: 10.33549/physiolres.934974. Epub 2022 Nov 25. Physiol Res. 2022. PMID: 36426888 Free PMC article.
-
Dose-Response Effects of 7-Dehydrocholesterol Reductase Inhibitors on Sterol Profiles and Vesicular Stomatitis Virus Replication.ACS Pharmacol Transl Sci. 2022 Oct 25;5(11):1086-1096. doi: 10.1021/acsptsci.2c00051. eCollection 2022 Nov 11. ACS Pharmacol Transl Sci. 2022. PMID: 36407960 Free PMC article.
-
Antiviral Potential of Plants against COVID-19 during Outbreaks-An Update.Int J Mol Sci. 2022 Nov 5;23(21):13564. doi: 10.3390/ijms232113564. Int J Mol Sci. 2022. PMID: 36362351 Free PMC article. Review.
-
Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOVery-SIRIO randomized trial.Cardiol J. 2022;29(5):739-750. doi: 10.5603/CJ.a2022.0072. Epub 2022 Aug 1. Cardiol J. 2022. PMID: 35912711 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous